The story "GlaxoSmithKline to Acquire Tesaro for $4.16 Billion--Update," published at 11:25 a.m. ET, incorrectly stated Glaxo expects results of a trial that could expand Zejula's use to earlier stages of ovarian cancer in the first half of next year. The drug company expects that result in the second half of next year (Dec. 3)

(END) Dow Jones Newswires

December 03, 2018 17:20 ET (22:20 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.
Tesaro, Inc. (NASDAQ:TSRO)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Tesaro, Inc..
Tesaro, Inc. (NASDAQ:TSRO)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Tesaro, Inc..